- Home
- CHCT vs RGNX Comparison
CHCT vs RGNX Comparison
Compare CHCT & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCT
- RGNX
- Stock Information
- Founded
- CHCT 2014
- RGNX 2008
- Country
- CHCT United States
- RGNX United States
- Employees
- CHCT N/A
- RGNX N/A
- Industry
- CHCT Real Estate Investment Trusts
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHCT Real Estate
- RGNX Health Care
- Exchange
- CHCT Nasdaq
- RGNX Nasdaq
- Market Cap
- CHCT 491.1M
- RGNX 424.8M
- IPO Year
- CHCT 2015
- RGNX 2015
- Fundamental
- Price
- CHCT $16.40
- RGNX $9.13
- Analyst Decision
- CHCT Buy
- RGNX Strong Buy
- Analyst Count
- CHCT 4
- RGNX 8
- Target Price
- CHCT $21.00
- RGNX $31.75
- AVG Volume (30 Days)
- CHCT 245.7K
- RGNX 583.4K
- Earning Date
- CHCT 07-29-2025
- RGNX 07-31-2025
- Dividend Yield
- CHCT 11.46%
- RGNX N/A
- EPS Growth
- CHCT N/A
- RGNX N/A
- EPS
- CHCT N/A
- RGNX N/A
- Revenue
- CHCT $116,531,000.00
- RGNX $156,718,000.00
- Revenue This Year
- CHCT $7.71
- RGNX $327.08
- Revenue Next Year
- CHCT $7.53
- RGNX N/A
- P/E Ratio
- CHCT N/A
- RGNX N/A
- Revenue Growth
- CHCT 1.33
- RGNX 80.70
- 52 Week Low
- CHCT $14.76
- RGNX $5.04
- 52 Week High
- CHCT $27.62
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- CHCT 45.91
- RGNX 55.09
- Support Level
- CHCT $15.92
- RGNX $8.14
- Resistance Level
- CHCT $16.57
- RGNX $8.94
- Average True Range (ATR)
- CHCT 0.46
- RGNX 0.49
- MACD
- CHCT -0.07
- RGNX 0.06
- Stochastic Oscillator
- CHCT 28.24
- RGNX 87.61
About CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.